| Literature DB >> 27701898 |
Victor Fattori1, Karla G G Serafim1, Ana C Zarpelon1, Sergio M Borghi1, Felipe A Pinho-Ribeiro1, José C Alves-Filho2, Thiago M Cunha2, Fernando Q Cunha2, Rúbia Casagrande3, Waldiceu A Verri1.
Abstract
The present study investigated whether endothelin-1 acts via ETA or ETB receptors to mediate superoxide anion-induced pain and inflammation. Mice were treated with clazosentan (ETA receptor antagonist) or BQ-788 (ETB receptor antagonist) prior to stimulation with the superoxide anion donor, KO2. Intraplantar treatment with 30 nmol of clazosentan or BQ-788 reduced mechanical hyperalgesia (47% and 42%), thermal hyperalgesia (68% and 76%), oedema (50% and 30%); myeloperoxidase activity (64% and 32%), and overt-pain like behaviours, such as paw flinching (42% and 42%) and paw licking (38% and 62%), respectively. Similarly, intraperitoneal treatment with 30 nmol of clazosentan or BQ-788 reduced leukocyte recruitment to the peritoneal cavity (58% and 32%) and abdominal writhing (81% and 77%), respectively. Additionally, intraplantar treatment with clazosentan or BQ-788 decreased spinal (45% and 41%) and peripheral (47% and 47%) superoxide anion production as well as spinal (47% and 47%) and peripheral (33% and 54%) lipid peroxidation, respectively. Intraplantar treatment with clazosentan, but not BQ-788, reduced spinal (71%) and peripheral (51%) interleukin-1 beta as well as spinal (59%) and peripheral (50%) tumor necrosis factor-alpha production. Therefore, the present study unveils the differential mechanisms by which ET-1, acting on ETA or ETB receptors, regulates superoxide anion-induced inflammation and pain.Entities:
Keywords: BQ-788; clazosentan; hyperalgesia; interleukin-1β; leukocyte recruitment; lipid peroxidation; nitric oxide; nociception; oedema; tumor necrosis factor-α
Mesh:
Substances:
Year: 2016 PMID: 27701898 DOI: 10.1080/1061186X.2016.1245308
Source DB: PubMed Journal: J Drug Target ISSN: 1026-7158 Impact factor: 5.121